In any case, the studies have been consistent in showing that IL-18 release in an immune-P2RX7-dependent manner is highly antitumoral, and suggesting that boosting the P2RX7/IL-18 pathway is promising for several types of cancer. This evidence concerns the gene P2RX7 and cancer.